Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa).

METHODS: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients.

RESULTS: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported.

CONCLUSIONS: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results. Advances in knowledge: The use of mpMRI to identify and boost the DIL is an innovative and interesting approach to PCa. Our preliminary findings suggest that dose escalation using DIL boost and extremely hypofractionated radiotherapy regimens might be a safe approach, allowing for short and effective treatment of organ-confined PCa.

Original languageEnglish
Pages (from-to)20160725
JournalThe British journal of radiology
Volume91
Issue number1089
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Prostatic Neoplasms
Radiotherapy
Therapeutics
Prostate
Appointments and Schedules

Keywords

  • Aged
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Prospective Studies
  • Prostate/diagnostic imaging
  • Prostatic Neoplasms/diagnostic imaging
  • Radiation Dose Hypofractionation
  • Radiotherapy Dosage
  • Radiotherapy, Computer-Assisted

Cite this

@article{e5e2949370944f99917a6d56b07fe984,
title = "Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218",
abstract = "OBJECTIVE: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa).METHODS: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients.RESULTS: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported.CONCLUSIONS: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results. Advances in knowledge: The use of mpMRI to identify and boost the DIL is an innovative and interesting approach to PCa. Our preliminary findings suggest that dose escalation using DIL boost and extremely hypofractionated radiotherapy regimens might be a safe approach, allowing for short and effective treatment of organ-confined PCa.",
keywords = "Aged, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies, Prostate/diagnostic imaging, Prostatic Neoplasms/diagnostic imaging, Radiation Dose Hypofractionation, Radiotherapy Dosage, Radiotherapy, Computer-Assisted",
author = "Giorgia Timon and Delia Ciardo and Alessia Bazani and Giulia Marvaso and Giulia Riva and Stefania Volpe and Rojas, {Damaris P} and Giuseppe Renne and Giuseppe Petralia and Dario Zerini and Cristiana Fodor and Samantha Dicuonzo and Davide Maestri and Floriana Pansini and Raffaella Cambria and Federica Cattani and Federica Golino and Valerio Scroffi and {De Lorenzo}, Daniela and {De Cobelli}, Ottavio and Roberto Orecchia and Jereczek-Fossa, {Barbara Alicja}",
year = "2018",
month = "9",
doi = "10.1259/bjr.20160725",
language = "English",
volume = "91",
pages = "20160725",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1089",

}

TY - JOUR

T1 - Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

T2 - ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218

AU - Timon, Giorgia

AU - Ciardo, Delia

AU - Bazani, Alessia

AU - Marvaso, Giulia

AU - Riva, Giulia

AU - Volpe, Stefania

AU - Rojas, Damaris P

AU - Renne, Giuseppe

AU - Petralia, Giuseppe

AU - Zerini, Dario

AU - Fodor, Cristiana

AU - Dicuonzo, Samantha

AU - Maestri, Davide

AU - Pansini, Floriana

AU - Cambria, Raffaella

AU - Cattani, Federica

AU - Golino, Federica

AU - Scroffi, Valerio

AU - De Lorenzo, Daniela

AU - De Cobelli, Ottavio

AU - Orecchia, Roberto

AU - Jereczek-Fossa, Barbara Alicja

PY - 2018/9

Y1 - 2018/9

N2 - OBJECTIVE: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa).METHODS: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients.RESULTS: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported.CONCLUSIONS: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results. Advances in knowledge: The use of mpMRI to identify and boost the DIL is an innovative and interesting approach to PCa. Our preliminary findings suggest that dose escalation using DIL boost and extremely hypofractionated radiotherapy regimens might be a safe approach, allowing for short and effective treatment of organ-confined PCa.

AB - OBJECTIVE: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa).METHODS: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients.RESULTS: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported.CONCLUSIONS: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results. Advances in knowledge: The use of mpMRI to identify and boost the DIL is an innovative and interesting approach to PCa. Our preliminary findings suggest that dose escalation using DIL boost and extremely hypofractionated radiotherapy regimens might be a safe approach, allowing for short and effective treatment of organ-confined PCa.

KW - Aged

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Prostate/diagnostic imaging

KW - Prostatic Neoplasms/diagnostic imaging

KW - Radiation Dose Hypofractionation

KW - Radiotherapy Dosage

KW - Radiotherapy, Computer-Assisted

U2 - 10.1259/bjr.20160725

DO - 10.1259/bjr.20160725

M3 - Article

C2 - 29750539

VL - 91

SP - 20160725

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1089

ER -